SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-18-014103
Filing Date
2018-10-18
Accepted
2018-10-18 17:12:13
Documents
5
Period of Report
2018-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k101918_actiniumpharma.htm 8-K 24715
2 OPINION OF THE MATT LAW FIRM, PLLC. f8k101918ex5-1_actinium.htm EX-5.1 9114
3 PURCHASE AGREEMENT, DATED AS OF OCTOBER 18, 2018, BY AND BETWEEN ACTINIUM PHARMA f8k101918ex10-1_actinium.htm EX-10.1 353649
4 REGISTRATION RIGHTS AGREEMENT, DATED AS OF OCTOBER 18, 2018, BY AND BETWEEN ACTI f8k101918ex10-2_actinium.htm EX-10.2 105914
5 GRAPHIC ex5-1_001.jpg GRAPHIC 21296
  Complete submission text file 0001213900-18-014103.txt   524071
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 181128886
SIC: 2834 Pharmaceutical Preparations